Literature DB >> 20697986

Clinical presentation of carcinoma of unknown primary: 14 years of experience.

Jun Ho Yi1, Yoon La Choi, Su Jin Lee, Hee Kyung Ahn, Kyung Kee Baek, Taekyu Lim, Duk Joo Lee, Bo Ram Han, Ha Yeon Lee, Hyun Jung Jun, Jeeyun Lee, Yeon Hee Park.   

Abstract

A carcinoma of unknown primary (CUP) is a histologically confirmed metastatic cancer without a definitive primary site after performing a detailed medical examination. The purpose of the study was to classify unfavorable CUPs into more reliable disease entities, which reflect the clinical course. We reviewed the medical records of patients diagnosed with a CUP between January 1995 and March 2008. Patients were classified into a conventional favorable-risk group and a newly proposed unfavorable-risk group according to the clinicopathologic features. Five hundred eighty-six patients were diagnosed with CUPs. Fifty-six (9.6%) patients were classified in the conventional favorable-risk group, and 486 (82.9%) patients were classified in the unfavorable-risk group. We further classified the 486 patients into six subgroups with an unfavorable risk, while excluding 29 patients (5.0%) who were not classifiable. The overall survival of the conventional favorable-risk group was 47.0 months (95% CI, 11.1~82.9 months), which was significantly longer than that of any subgroup of the newly proposed unfavorable-risk group (P < 0.001). Patients with squamous cell carcinoma in the abdominopelvic cavity showed similar overall survival with unfavorable-risk group (P = 0.484). Women with non-papillary malignant ascites had a survival in between the favorable and unfavorable groups (P <  0.001). The newly proposed unfavorable-risk group may assist in classifying CUP patients with an unfavorable risk in a clinically more meaningful way. Squamous cell carcinoma in the abdominopelvic cavity should be considered in the unfavorable-risk group and women with non-papillary malignant ascites in an intermediate-risk group. Further studies with molecular profiling would help in classifying and treating patients with CUPs and an unfavorable risk.

Entities:  

Mesh:

Year:  2010        PMID: 20697986     DOI: 10.1007/s13277-010-0089-6

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  18 in total

1.  Prognostic factors in metastatic carcinoma of unknown primary.

Authors:  R Pasterz; N Savaraj; M Burgess
Journal:  J Clin Oncol       Date:  1986-11       Impact factor: 44.544

2.  Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992.

Authors:  A J van de Wouw; M L G Janssen-Heijnen; J W W Coebergh; H F P Hillen
Journal:  Eur J Cancer       Date:  2002-02       Impact factor: 9.162

3.  Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study.

Authors:  M Saghatchian; K Fizazi; C Borel; M Ducreux; P Ruffié; T Le Chevalier; C Théodore
Journal:  Ann Oncol       Date:  2001-04       Impact factor: 32.976

Review 4.  Cervical lymph node metastases from occult squamous cell carcinoma: cut down a tree to get an apple?

Authors:  C Nieder; V Gregoire; K K Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-07-01       Impact factor: 7.038

5.  Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome.

Authors:  F A Greco; W K Vaughn; J D Hainsworth
Journal:  Ann Intern Med       Date:  1986-04       Impact factor: 25.391

6.  Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity.

Authors:  J D Hainsworth; D H Johnson; F A Greco
Journal:  Ann Intern Med       Date:  1988-09-01       Impact factor: 25.391

Review 7.  Cancer of unknown primary site: missing primary or missing biology?

Authors:  George Pentheroudakis; Evangelos Briasoulis; Nicholas Pavlidis
Journal:  Oncologist       Date:  2007-04

Review 8.  Tumors of unknown origin.

Authors:  F A Greco; J D Hainsworth
Journal:  CA Cancer J Clin       Date:  1992 Mar-Apr       Impact factor: 508.702

Review 9.  Diagnostic and therapeutic management of cancer of an unknown primary.

Authors:  N Pavlidis; E Briasoulis; J Hainsworth; F A Greco
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162

10.  Raising the profile of cancer of unknown primary.

Authors:  Karin A Oien; T R Jeffry Evans
Journal:  J Clin Oncol       Date:  2008-09-20       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.